Targacept, a developer of a new class of drugs to treat central nervous system diseases, announced Thursday that it will offer 5.0 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will have an initial market capitalization of $244 million. Deutsche Bank and Pacific Growth Equities are the head underwriters on the deal. Timing has yet to be disclosed.
